Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).
about
Chronic hepatitis C: This and the new era of treatmentCharacterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175Postexposure prophylaxis after hepatitis C occupational exposure in the interferon-free eraReal-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt.Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.Characterization of the anti-hepatitis C virus activity of new non-peptidic small-molecule cyclophilin inhibitors with a potential for broad anti-Flaviviridae activity.
P2860
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Randomised clinical trial: ali ...... pe 1 infection (ESSENTIAL II).
@ast
Randomised clinical trial: ali ...... pe 1 infection (ESSENTIAL II).
@en
type
label
Randomised clinical trial: ali ...... pe 1 infection (ESSENTIAL II).
@ast
Randomised clinical trial: ali ...... pe 1 infection (ESSENTIAL II).
@en
prefLabel
Randomised clinical trial: ali ...... pe 1 infection (ESSENTIAL II).
@ast
Randomised clinical trial: ali ...... pe 1 infection (ESSENTIAL II).
@en
P2093
P2860
P356
P1476
Randomised clinical trial: ali ...... pe 1 infection (ESSENTIAL II).
@en
P2093
D Abdurakhmanov
ESSENTIAL II Study Group
J M Vierling
L H Griffel
P2860
P304
P356
10.1111/APT.13342
P407
P577
2015-08-04T00:00:00Z